TechnoPhage is an innovative biopharmaceutical company committed to the R&D of new molecules - chemical and biological - in diverse therapeutic areas, such as infection, neuroscience, and immunology. TechnoPhage’s strategy is based on developing new therapeutics in early phases of R&D, with a view to then enter into collaboration deals for pre-clinical and/or clinical development.
TechnoPhage is developing proprietary drug discovery products from discovery to clinical stage. The company has several patents in place and successfully developed one of its products into clinical Phase I. TechnoPhage is focused on increasing its portfolio of proprietary technologies and deriving products. This is achieved through an active R&D program and collaboration agreements with national and international pharmaceutical companies, research centers and universities across the US, Europe and Asia.
The company’s laboratories are located at IMM, in Lisbon, under a scientific collaboration protocol signed by both entities. Close proximity to the renowned Santa Maria Hospital and the IMM help facilitate the creation of multidisciplinary teams essential to the process of translational medicine. Furthermore this proximity helps to facilitate access to the necessary equipment and talent required to develop full product solutions, including direct collaboration with leading experts from the clinical fields covering the therapeutic products under development.
Launched in 2005 as a stand-alone drug discovery and development company, TechnoPhage is headquartered in Lisbon, Portugal. The company has developed three proprietary drug discovery platforms with several technology/product patent applications filed and granted. Since inception, the company has signed numerous agreements and partnerships with both academic and industrial partners, developing growth and progressively increasing the company’s R&D activities.
TechnoPhage has a longstanding relationship with the IMM and presently leverages its high-quality facilities and resources. The company’s unique access to equipment and talent at the IMM and other research institutions is essential to translational medicine and development of full product solutions.
Based on over 10 years of R&D, TechnoPhage is now in a position to bring its products to commercial stage, and is entering a new growth phase - clinical trials - for the development of a bacteriophage cocktail for the treatment of chronic ulcers (TP-102).
The company is led by a management team with large experience in pharmaceuticals, including drug discovery and development. In addition, TechnoPhage benefits from its Scientific Advisory Board, comprising top experts with significant experience in their respective fields adding significant value to the R&D and product development activities of the company.